{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:32:50Z","timestamp":1778272370435,"version":"3.51.4"},"reference-count":38,"publisher":"American Society of Hematology","issue":"2","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>High-risk multiple myeloma (MM) is often defined based on cytogenetic abnormalities, but patients who relapse early after initial therapy are considered a functional high-risk group. In the phase 3 CASTOR and POLLUX studies, daratumumab plus bortezomib\/dexamethasone (D-Vd) or lenalidomide\/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS), regardless of cytogenetic risk, and achieved higher rates of complete response or better (\u2265CR) and minimal residual disease (MRD) negativity vs that with Vd\/Rd alone in relapsed\/refractory MM. Post hoc analyses of CASTOR and POLLUX evaluated patient subgroups with 1 prior line of therapy based on timing of progression\/relapse (early or late) after initiation of first line of therapy. PFS consistently favored the daratumumab-containing regimens across subgroups using both a 24- and 18-month early-relapse cutoff. In the CASTOR\/POLLUX pooled data set, daratumumab reduced the risk of disease progression or death by 65% (hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.26-0.48; P\u00a0&amp;lt; .0001) in the early-relapse (&amp;lt;24\u00a0months) subgroup and by 65% (HR, 0.35; 95%\u00a0CI, 0.26-0.47; P\u00a0&amp;lt; .0001) in the late-relapse (\u226524\u00a0months) subgroup. OS also favored the daratumumab-containing regimens in both the early-relapse (HR, 0.62; 95%\u00a0CI, 0.45-0.86; P\u00a0= .0036) and late-relapse (HR, 0.67; 95%\u00a0CI, 0.48-0.93; P\u00a0= .0183) subgroups in the pooled population using a 24-month cutoff. Rates of \u2265CR and MRD negativity (10\u22125) were higher with daratumumab vs control, regardless of progression\/relapse timing. Although daratumumab is unable to fully overcome the adverse prognosis of early relapse, our results support the use of daratumumab for patients with 1 prior line of therapy, including for those who progress\/relapse early after initial therapy and are considered to have functional high-risk MM. These trials were registered at www.clinicaltrials.gov as #NCT02136134 (CASTOR) and #NCT02076009 (POLLUX).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010579","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T19:01:35Z","timestamp":1701716495000},"page":"388-398","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX"],"prefix":"10.1182","volume":"8","author":[{"given":"Andrew","family":"Spencer","sequence":"first","affiliation":[{"name":"1Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"2Hematology Department, University Hospital H\u00f4tel-Dieu, Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"3University Hospital of Salamanca\/Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\/Centre for Cancer Research Institute of Cancer Molecular and Cellular Biology, Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"4University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7132-5337","authenticated-orcid":false,"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[{"name":"6Albert Schweitzer Hospital, Dordrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0808-2237","authenticated-orcid":false,"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"7Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"8Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-7459","authenticated-orcid":false,"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"10Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"11Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Reece","sequence":"additional","affiliation":[{"name":"12Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahamtan","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"13Genmab US, Inc, Plainsboro, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiling","family":"Pei","sequence":"additional","affiliation":[{"name":"14Janssen Research & Development, LLC, Titusville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy Garvin","family":"Mayo","sequence":"additional","affiliation":[{"name":"15Janssen Research & Development, LLC, Raritan, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Gai","sequence":"additional","affiliation":[{"name":"16Janssen Research & Development, LLC, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jodi","family":"Carey","sequence":"additional","affiliation":[{"name":"17Janssen Research & Development, LLC, Spring House, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Blake","family":"Bartlett","sequence":"additional","affiliation":[{"name":"15Janssen Research & Development, LLC, Raritan, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[{"name":"17Janssen Research & Development, LLC, Spring House, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"18National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"issue":"12","key":"2024011922111532300_bib1","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.6004\/jnccn.2020.7673","article-title":"Defining and managing high-risk multiple myeloma: current concepts","volume":"18","author":"Costa","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"8","key":"2024011922111532300_bib2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"11","key":"2024011922111532300_bib3","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2016.147","article-title":"Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents","volume":"30","author":"Majithia","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"2024011922111532300_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00576-3","article-title":"Genomic characterization of functional high-risk multiple myeloma patients","volume":"12","author":"Soekojo","year":"2022","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2024011922111532300_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1182\/blood-2019-129431","article-title":"Real-world outcome for newly diagnosed patients with functional high-risk myeloma \u2013 a Myeloma and Related Diseases Registry analysis","volume":"134","author":"Spencer","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2024011922111532300_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-142629","article-title":"Real-world treatment patterns and outcomes of patients with functional high-risk (early relapse) multiple myeloma","volume":"136","author":"Belli","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2024011922111532300_bib7","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"21","key":"2024011922111532300_bib8","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","article-title":"Direct in\u00a0vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79","volume":"124","author":"Lammerts van Bueren","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2024011922111532300_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"issue":"3","key":"2024011922111532300_bib10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"2024011922111532300_bib11","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2024011922111532300_bib12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cyto.a.23693","article-title":"High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action","volume":"95","author":"Adams","year":"2019","journal-title":"Cytometry A"},{"issue":"2","key":"2024011922111532300_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41375-020-0855-4","article-title":"Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab","volume":"35","author":"Casneuf","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"2024011922111532300_bib14","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3324\/haematol.2020.268656","article-title":"Comparison of CD38 antibodies in\u00a0vitro and ex\u00a0vivo mechanisms of action in multiple myeloma","volume":"106","author":"Kinder","year":"2021","journal-title":"Haematologica"},{"issue":"10192","key":"2024011922111532300_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"2024011922111532300_bib16","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"2024011922111532300_bib17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10218","key":"2024011922111532300_bib18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"22","key":"2024011922111532300_bib19","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024011922111532300_bib20","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"2024011922111532300_bib21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","article-title":"Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR","volume":"20","author":"Mateos","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2024011922111532300_bib22","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024011922111532300_bib23","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"2024011922111532300_bib24","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024011922111532300_bib25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024011922111532300_bib26","volume-title":"DARZALEX (daratumumab) injection. Package insert","year":"2022"},{"key":"2024011922111532300_bib27","unstructured":"European Medicines Agency\n          . DARZALEX 20 mg\/mL concentrate for solution for infusion [summary of product characteristics]. Accessed 11 October 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/darzalex-epar-product-information_en.pdf."},{"issue":"8","key":"2024011922111532300_bib28","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2024011922111532300_bib29","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024011922111532300_bib30","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"18","key":"2024011922111532300_bib31","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"2024011922111532300_bib32","author":"Weisel","year":"2020"},{"key":"2024011922111532300_bib33","author":"Facon","year":"2022"},{"key":"2024011922111532300_bib34","author":"van de Donk","year":"2022"},{"key":"2024011922111532300_bib35","author":"Usmani","year":"2022"},{"key":"2024011922111532300_bib36","author":"Lim","year":"2022"},{"issue":"2","key":"2024011922111532300_bib37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"2024011922111532300_bib38","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2024013112","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/388\/2210474\/blooda_adv-2023-010579-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/388\/2210474\/blooda_adv-2023-010579-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T22:12:08Z","timestamp":1705702328000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/2\/388\/506492\/Daratumumab-for-patients-with-myeloma-with-early"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010579","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2024013112","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]}}}